8-K: Krystal Biotech Launches VYJUVEK in Japan

Krystal Biotech's subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK in Japan for dystrophic epidermolysis bullosa, following its inclusion on the NHI Drug Price List.

Summary

• Krystal Biotech, Inc. announced the commercial launch of VYJUVEK (beremagene geperpavec) in Japan.
• The launch, effective October 22, 2025, is for the treatment of dystrophic epidermolysis bullosa (DEB).
• VYJUVEK has been included on Japan's National Health Insurance (NHI) Drug Price List.
• The listed price for VYJUVEK on the NHI Drug Price List is 2,955,232.7 yen per unit.
• The commercialization efforts in Japan are being led by Krystal Biotech's wholly owned subsidiary, Krystal Biotech Japan KK.

Sentiment

Score: 9

Explanation: The successful commercial launch of a key product in a major international market, coupled with favorable pricing and reimbursement, is a highly positive development for the company's growth and financial prospects.

Positives

• Successful commercial launch of VYJUVEK in Japan, expanding market reach for the gene therapy.
• Inclusion of VYJUVEK on Japan's National Health Insurance (NHI) Drug Price List, ensuring reimbursement and patient access.
• A specific price of 2,955,232.7 yen per unit has been established, providing clear revenue potential.

Future Outlook

The commercial launch of VYJUVEK in Japan, following its inclusion on the National Health Insurance Drug Price List, establishes a new revenue stream and significantly expands the global market presence for Krystal Biotech's lead product.

Management Comments

• Krystal Biotech reported the commercial launch of VYJUVEK in Japan for dystrophic epidermolysis bullosa, effective October 22, 2025, following its inclusion on the NHI Drug Price List.

Industry Context

This announcement marks a significant expansion for Krystal Biotech into the Japanese market, a key region for pharmaceutical innovation and rare disease treatments. The successful commercialization of a gene therapy like VYJUVEK in a major developed market like Japan underscores the growing acceptance and reimbursement pathways for advanced therapeutic medicinal products globally, setting a precedent for other gene therapy developers.

Stakeholder Impact

• Shareholders: Positive impact due to expanded market access, new revenue streams, and potential for increased profitability.
• Patients with DEB in Japan: Positive impact through access to a new approved treatment, VYJUVEK, with national health insurance coverage.
• Employees: Positive impact due to successful product launch and market expansion, potentially leading to job security and growth opportunities.

Next Steps

• Continued commercialization and distribution efforts for VYJUVEK in Japan through Krystal Biotech Japan KK.

Key Dates

Recommendation

The successful commercial launch of VYJUVEK in Japan, a significant pharmaceutical market, coupled with its inclusion on the National Health Insurance Drug Price List at a specific unit price, represents a substantial positive catalyst. This milestone provides a clear path to revenue generation in a key global market, significantly de-risks the product's international commercialization, and indicates strong future growth potential, making the stock highly attractive for investment.

Keywords

Krystal Biotech, VYJUVEK, beremagene geperpavec, dystrophic epidermolysis bullosa, DEB, Japan, commercial launch, NHI, drug price list, gene therapy, rare disease